Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8536998 | Pharmacology & Therapeutics | 2017 | 44 Pages |
Abstract
Increased levels of tumor necrosis factor (TNF) α have been linked to a number of pulmonary inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), sarcoidosis, and interstitial pulmonary fibrosis (IPF). TNFα plays multiple roles in disease pathology by inducing an accumulation of inflammatory cells, stimulating the generation of inflammatory mediators, and causing oxidative and nitrosative stress, airway hyperresponsiveness and tissue remodeling. TNFα-targeting biologics, therefore, present a potentially highly efficacious treatment option. This review summarizes current knowledge on the role of TNFα in pulmonary disease pathologies, with a focus on the therapeutic potential of TNFα-targeting agents in treating inflammatory lung diseases.
Keywords
BALTNFα-converting enzymeTNFARDSTACEAP-1FVCIPFLPSNF-κBTNFαTGFβLung injuryAcute lung injuryinflammationAliinterleukinPulmonary diseaseChronic obstructive pulmonary diseaseCOPDBiologicsTransforming growth factor βAcute respiratory distress syndromeforced vital capacitytumor necrosis factorNuclear factor-kappa BInterstitial pulmonary fibrosisbronchoalveolar lavagelipopolysaccharideActivated protein 1Glucocorticoids
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Rama Malaviya, Jeffrey D. Laskin, Debra L. Laskin,